IL6 and COVID-19: Thus far, the utilization of monoclonal antibodies (mAB) against IL-6, such as Tocilizumab, has been considered according to evidence of a dramatic increase in proinflammatory cytokine IL6 in patients infected by COVID-19, leading to an increased generalized cytokine release and inflammation in lungs [87,88].